Position statement on the use of bortezomib in multiple myeloma

被引:7
|
作者
Morgan, G. J. [1 ]
Davies, F. E. [1 ]
Cavenagh, J. D. [2 ]
Jackson, G. H. [3 ]
机构
[1] Royal Marsden Hosp, Haemato Oncol Unit, London SW3 6JJ, England
[2] St Bartholomews & Royal London Hosp, Dept Haematol, London, England
[3] Royal Victoria Hosp, Dept Haematol, Newcastle, NSW, Australia
关键词
myeloma; bortezomib; proteasome inhibition; relapse therapy;
D O I
10.1111/j.1751-553X.2007.01020.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bortezomib (Velcade (TM)) is a boron containing molecule which reversibly inhibits the proteasome, an intracellular organelle which is central to the breakdown of ubiquinated proteins and consequently crucial for normal cellular homeostasis. Phase II clinical trials demonstrate it is effective for the treatment of relapsed refractory myeloma, and a phase III trial comparing bortezomib to dexamethasone in second/third line treatment showed superiority in progression free and overall survival. It is administered intravenously in the outpatient setting on days 1, 4, 8 and 11 of a 21-day cycle and regular monitoring for side effects is essential. It is currently approved for the treatment of multiple myeloma patients who have received at least one prior therapy and who have already undergone or are unsuitable for transplantation. Given the strength of this data the UK Myeloma Forum and British Committee for Standards in Haematology believe that bortezomib should be available for prescription by UK haematologists according to its licensed indication in patients with relapsed myeloma.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [42] Bortezomib and dexamethasone induction for multiple myeloma
    Jacob Laubach
    Paul Richardson
    Nature Reviews Clinical Oncology, 2011, 8 : 8 - 10
  • [43] Bortezomib Combination Therapy in Multiple Myeloma
    Kapoor, Prashant
    Ramakrishnan, Vijay
    Rajkumar, S. Vincent
    SEMINARS IN HEMATOLOGY, 2012, 49 (03) : 228 - 242
  • [44] Bortezomib in newly diagnosed multiple myeloma
    Berenson, James R.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 255 - 256
  • [45] Bortezomib for previously untreated multiple myeloma
    Delforge, Michel
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (16) : 2553 - 2564
  • [46] Bortezomib for the treatment of multiple myeloma patients
    Green, C.
    Bryant, J.
    Takeda, A.
    Cooper, K.
    Clegg, A.
    Smith, A.
    Stephens, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 29 - 33
  • [47] Cutaneous involvement in multiple myeloma and bortezomib
    A. Siniscalchi
    S. Fratoni
    G. Santeusanio
    G. Del Poeta
    P. de Fabritiis
    T. Caravita
    Annals of Hematology, 2009, 88 : 1137 - 1139
  • [48] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    Palumbo, Antonio
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria V.
    Mark, Tomer M.
    Qi, Ming
    Schecter, Jordan
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 754 - 766
  • [49] Bortezomib in newly diagnosed multiple myeloma
    James R. Berenson
    Nature Reviews Clinical Oncology, 2009, 6 : 255 - 256
  • [50] Bortezomib Alone and PAD in Multiple Myeloma
    Kraj, M. A.
    Warzocha, K.
    Poglod, R.
    Kwasniak, B.
    Szpila, T.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S3 - S3